AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body's immune system, announced that the U.S. Patent and Trademark Office recently issued the company a patent related to the company's PADRE technology.
The patent, United States Patent Number 6,413,935 entitled, "Induction of Immune Response Against Desired Determinants," includes claims covering the induction of immune responses using the company's PADRE technology combined with disease-specific antigens. The patent also includes claims addressing different types of disease-specific antigens including proteins, lipids, and other immunogens - important targets for most infectious diseases, cancers, and autoimmune diseases.
PADRE, a family of small, synthetic proprietary molecules that are potent immunostimulants, is used in Epimmune's therapeutic and preventative vaccine programs including those targeting HIV and lung and colon cancers.
Epimmune has also licensed PADRE to other companies for use in inducing immune responses against a variety of disease antigens, including Genencor for use in their ...
Source: HighBeam Research, Additional patent issued for PADRE technology.(Brief Article)